

29 November 2022

## **STRATEGIC STAKE AND COMMERCIAL PARTNERSHIP WITH MICROBA**

Sonic Healthcare (ASX: SHL; ADR: SKHHY) ('Sonic') is pleased to announce that it has agreed to invest A\$17.8 million to acquire a 19.99% shareholding in Microba Life Sciences Limited (ASX: MAP) ('Microba'). In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to approval by Microba's shareholders.

Sonic and Microba have agreed initial terms of a strategic alliance to exclusively deliver Microba's microbiome testing technology into Germany, the United Kingdom and Belgium, along with non-exclusive distribution into Sonic's broader network including Australia, Switzerland, the United States and New Zealand.

Sonic Healthcare's Chief Medical Officer, Dr Stephen Fairy, will join Microba's Medical Advisory Board, responsible for governing the medical and scientific direction of Microba's commercial activities.

Sonic Healthcare's Chief Executive Officer, Dr Colin Goldschmidt said: "Sonic Healthcare prides itself on delivering accurate, reliable medical diagnostics services using leading laboratory and informatics technologies. Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities that Microba's technology will provide for Sonic's global operations, our referring clinicians, and our patients."

### **About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit: [www.microba.com](http://www.microba.com)

The transaction is not considered to be material for Sonic. This announcement has been authorised by Sonic Healthcare's Managing Director. For further information regarding this announcement, please contact:

**Dr Colin Goldschmidt**  
CEO  
Sonic Healthcare  
Telephone: +612 9855 5333  
Email: [colgold@msn.com.au](mailto:colgold@msn.com.au)

**Chris Wilks**  
CFO  
Sonic Healthcare  
Telephone: +612 9855 5404  
Email: [cdwilks@bigpond.com](mailto:cdwilks@bigpond.com)